|
|
PLPP6 |
phospholipid phosphatase 6 |
|
|
|
|
|
PNLIPRP1 |
pancreatic lipase related protein 1 |
- Digestion of dietary lipid
|
|
|
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Sulfasalazine
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Type II diabetes mellitus
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Thyroid cancer
|
|
|
PPIF |
peptidylprolyl isomerase F |
|
- Cyclosporine
- Proline
- Triglyme
- Coumarin 120
|
|
|
|
PRKCD |
protein kinase C delta |
- Apoptotic cleavage of cellular proteins
- Calmodulin induced events
- Effects of PIP2 hydrolysis
- SHC1 events in ERBB2 signaling
- DAG and IP3 signaling
- Role of phospholipids in phagocytosis
- G alpha (z) signalling events
- HuR (ELAVL1) binds and stabilizes mRNA
- VEGFR2 mediated cell proliferation
- CLEC7A (Dectin-1) signaling
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Interferon gamma signaling
|
- Tamoxifen
- 13-Acetylphorbol
- Ingenol mebutate
- Fostamatinib
|
|
|
|
RFT1 |
RFT1 homolog |
- Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
- Defective RFT1 causes RFT1-CDG (CDG-1n)
|
|
- Congenital disorders of glycosylation (CDG) type I
|
|
|
RHD |
Rh blood group D antigen |
- Rhesus blood group biosynthesis
|
|
|
|
|
SCAMP5 |
secretory carrier membrane protein 5 |
|
|
|
|
|
SELENOK |
selenoprotein K |
|
|
|
|
|
SERP2 |
stress associated endoplasmic reticulum protein family member 2 |
|
|
|
|
|
SFTPC |
surfactant protein C |
- Surfactant metabolism
- Defective pro-SFTPC causes SMDP2 and RDS
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
|
|
- Pulmonary surfactant metabolism dysfunction (SMDP)
|
|
|
SIGLEC1 |
sialic acid binding Ig like lectin 1 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
- Beta-D-Glucose
- N-acetyl-alpha-neuraminic acid
|
|
|
|
SLC22A1 |
solute carrier family 22 member 1 |
- Neurotransmitter clearance
- Norepinephrine Neurotransmitter Release Cycle
- Abacavir transmembrane transport
- Na+/Cl- dependent neurotransmitter transporters
- Organic cation transport
|
|
|
|
|
SLC30A8 |
solute carrier family 30 member 8 |
- Insulin processing
- Zinc efflux and compartmentalization by the SLC30 family
|
|
- Type II diabetes mellitus
|
|
|
SLC35B4 |
solute carrier family 35 member B4 |
- Transport of nucleotide sugars
|
|
|
|
|
SLC35E4 |
solute carrier family 35 member E4 |
|
|
|
|
|
SLC38A7 |
solute carrier family 38 member 7 |
|
|
|
|
|
SMCO4 |
single-pass membrane protein with coiled-coil domains 4 |
|
|
|
|
|
SMIM1 |
small integral membrane protein 1 (Vel blood group) |
|
|
|
|
|
SOS1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
- SOS-mediated signalling
- SOS-mediated signalling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Signalling to RAS
- Signalling to RAS
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- NRAGE signals death through JNK
- Rho GTPase cycle
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- SHC-related events triggered by IGF1R
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- NCAM signaling for neurite out-growth
- G alpha (12/13) signalling events
- Activation of RAC1
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- MET activates RAS signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Interleukin-15 signaling
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- Interleukin receptor SHC signaling
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|